3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Stomach Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Leukemia, Biphenotypic, Acute
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Burkitt Lymphoma
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
18
Paclitaxel
13
Carboplatin
10
Pemetrexed
4
Cisplatin
4
patritumab deruxtecan
3
Gemcitabine
3
Docetaxel
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
Histamine H2 Antagonists
2
Histamine Antagonists
2
Dexamethasone
2
Acetaminophen
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
osimertinib
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Serotonin 5-HT3 Receptor Antagonists
1
Ramucirumab
1
Oxaliplatin
1
Neurokinin-1 Receptor Antagonists
1
Neoadjuvant Therapy
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Levoleucovorin
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled